文献速递胸部肿瘤头颈与中枢神经肿瘤

恩曲替尼治疗ROS1融合阳性非小细胞肺癌:三项1-2期试验整合分析

Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.
PubMed 文献 · Lancet Oncol · 2019-12-11

该整合分析纳入三项1-2期试验中接受恩曲替尼≥600 mg每日一次治疗的ROS1融合阳性晚期NSCLC患者,疗效可评估53例中41例(77%;安全性可评估134例中多数治疗相关不良事件为1-2级,无治疗相关死亡。

要点

  • 安全性可评估134例中3-4级治疗相关不良事件34%,常见为体重增加和中性粒细胞减少。
  • 结果支持对ROS1融合阳性NSCLC常规检测ROS1融合以拓宽治疗选择。

核心结论

  • 恩曲替尼在ROS1融合阳性NSCLC中具有活性且疾病控制持久,耐受性良好,适合长期给药。

研究设计与样本

  • 整合分析三项正在进行的1期或2期试验(ALKA-372-001、STARTRK-1、STARTRK-2)。
  • 疗效可评估人群为接受恩曲替尼至少600 mg口服每日一次、随访至少12个月的成人ROS1融合阳性局部晚期或转移性NSCLC患者。
  • 安全性可评估人群为三项试验中接受至少一剂恩曲替尼的所有ROS1融合阳性NSCLC患者,不论剂量或随访时长。

主要发现

  • 安全性可评估134例中79例(59%)发生1或2级治疗相关不良事件,46例(34%)发生3或4级治疗相关不良事件。
  • 最常见的3或4级治疗相关不良事件为体重增加(10例[8%])和中性粒细胞减少(5例[4%])。
  • 15例(11%)发生严重治疗相关不良事件,最常见为神经系统疾病(4例[3%])和心脏疾病(3例[2%]),无治疗相关死亡。

关键数值与推荐

  • 客观缓解定义为根据RECIST 1.1版达到完全或部分缓解,由盲法独立中心审查评估。

临床怎么用

  • 恩曲替尼可用于ROS1融合阳性晚期NSCLC,且因安全性可控适合长期给药。
  • 临床应常规检测ROS1融合以识别可从恩曲替尼治疗中获益的患者。

局限性

  • 为三项1-2期试验的整合分析,非随机对照研究。
  • 疗效可评估人群样本量为53例,安全性可评估人群为134例。
  • STARTRK-2试验入组仍在进行中。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recurrent gene fusions, such as ROS1 fusions, are oncogenic drivers of various cancers, including non-small-cell lung cancer (NSCLC). Up to 36% of patients with ROS1 fusion-positive NSCLC have brain metastases at the diagnosis of advanced disease. Entrectinib is a ROS1 inhibitor that has been designed to effectively penetrate and remain in the CNS. We explored the use of entrectinib in patients with locally advanced or metastatic ROS1 fusion-positive NSCLC. METHODS: We did an integrated analysis of three ongoing phase 1 or 2 trials of entrectinib (ALKA-372-001, STARTRK-1, and STARTRK-2). The efficacy-evaluable population included adult patients (aged ≥18 years) with locally advanced or metastatic ROS1 fusion-positive NSCLC who received entrectinib at a dose of at least 600 mg orally once per day, with at least 12 months' follow-up. All patients had an Eastern Cooperative Oncology Group performance status of 0-2, and previous cancer treatment (except for ROS1 inhibitors) was allowed. The primary endpoints were the proportion of patients with an objective response (complete or partial response according to Response Evaluation Criteria in Solid Tumors version 1.1) and duration of response, and were evaluated by blinded independent central review. The safety-evaluable population for the safety analysis included all patients with ROS1 fusion-positive NSCLC in the three trials who received at least one dose of entrectinib (irrespective of dose or duration of follow-up). These ongoing studies are registered with ClinicalTrials.gov, NCT02097810 (STARTRK-1) and NCT02568267 (STARTRK-2), and EudraCT, 2012-000148-88 (ALKA-372-001). FINDINGS: Patients were enrolled in ALKA-372-001 from Oct 26, 2012, to March 27, 2018; in STARTRK-1 from Aug 7, 2014, to May 10, 2018; and in STARTRK-2 from Nov 19, 2015 (enrolment is ongoing). At the data cutoff date for this analysis (May 31, 2018), 41 (77%; 95% CI 64-88) of 53 patients in the efficacy-evaluable population had an objective response. Median follow-up was 15·5 monhts (IQR 13·4-20·2). Median duration of response was 24·6 months (95% CI 11·4-34·8). In the safety-evaluable population, 79 (59%) of 134 patients had grade 1 or 2 treatment-related adverse events. 46 (34%) of 134 patients had grade 3 or 4 treatment-related adverse events, with the most common being weight increase (ten [8%]) and neutropenia (five [4%]). 15 (11%) patients had serious treatment-related adverse events, the most common of which were nervous system disorders (four [3%]) and cardiac disorders (three [2%]). No treatment-related deaths occurred. INTERPRETATION: Entrectinib is active with durable disease control in patients with ROS1 fusion-positive NSCLC, and is well tolerated with a manageable safety profile, making it amenable to long-term dosing in these patients. These data highlight the need to routinely test for ROS1 fusions to broaden therapeutic options for patients with ROS1 fusion-positive NSCLC. FUNDING: Ignyta/F Hoffmann-La Roche.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Drilon A, Siena S, Dziadziuszko R, et al. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2019. PMID: 31838015. doi:10.1016/S1470-2045(19)30690-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。